Impact of Neurolens Use on the Quality of Life in Individuals With Headaches: A Randomized Double-Masked, Cross-Over Clinical Trial

Vision-related disorders, such as refractive errors and binocular vision issues, can cause headaches. The current study evaluates the impact of Neurolens (NL) on individuals with headaches, assessed using the Headache Impact Test (HIT) questionnaire. Subjects (18-60 years) with good stereoacuity and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational vision science & technology 2024-01, Vol.13 (1), p.27-27
Hauptverfasser: Labhishetty, Vivek, Cortes, Jesus, van de Pol, Corina, Maanpaa, Ville, Plumley, Aric, Amin, Neha, Hurley, Jason, Barton, Tausha, White, Troy, Szeliga, Rob, Dixon, J Mathis, Grosswald, David, Knutson, Jon, Maier, Heavin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Vision-related disorders, such as refractive errors and binocular vision issues, can cause headaches. The current study evaluates the impact of Neurolens (NL) on individuals with headaches, assessed using the Headache Impact Test (HIT) questionnaire. Subjects (18-60 years) with good stereoacuity and a HIT score of ≥56 points were enrolled. Each subject wore both control lens and NL for 30 ± 10 days each. The primary outcome of the study was to assess the difference in the HIT score between the two treatments. Of the subjects randomized, 88% (170/195) completed the study. Overall, subjects reported a greater improvement in HIT score improvement with NL compared with control (mean difference, -1.53 points; 95% confidence interval, -2.8 to -0.26; P = 0.01). In the subgroup with reduced NPC, subjects reported a larger improvement in HIT score improvement with NL but was not statistically significant (mean difference, -1.89 points; 95% confidence interval, -4.27 to -0.47; P = 0.11). NL produced a statistically significant decrease in the impact of headaches on individuals' quality of life compared with placebo. Although the overall magnitude of the decrease was not clinically significant, a clinically meaningful improvement with NL cannot be ruled out with high certainty in the current study. Headache is one of the most experienced symptoms by individuals worldwide with vision-related disorders being a primary reason. It is, therefore, critical to screen these disorders before providing a pharmacological intervention, which may have side effects. NL provides an objective way to diagnose and treat digital eyestrain-related headaches.
ISSN:2164-2591
2164-2591
DOI:10.1167/tvst.13.1.27